Weight loss pills for perimenopause are an increasingly common topic as women navigate the hormonal, metabolic, and lifestyle changes of this transitional phase. Perimenopause — typically beginning in the mid-to-late 40s — brings fluctuating oestrogen and progesterone levels that can shift fat distribution towards the abdomen and make weight management more challenging. Several licensed medications are available in the UK to support weight loss, but none are specifically indicated for perimenopause. This article explains how these treatments work, who may be eligible on the NHS, what safety considerations apply, and why lifestyle changes remain central to any effective weight management plan.
Summary: Weight loss pills for perimenopause include GLP-1 receptor agonists such as semaglutide and liraglutide, orlistat, and naltrexone/bupropion — all prescribed under standard UK weight-management criteria rather than for perimenopause specifically.
- No weight loss medication is specifically licensed for perimenopause; prescribing is based on BMI thresholds, comorbidities, and NICE eligibility criteria.
- GLP-1 receptor agonists (semaglutide/Wegovy, liraglutide/Saxenda) are the most clinically significant options and must be initiated within a specialist NHS weight management service.
- Orlistat reduces dietary fat absorption and can be started in primary care; it reduces fat-soluble vitamin absorption, so a daily multivitamin is routinely recommended.
- Naltrexone/bupropion (Mysimba) is licensed in the UK but not routinely commissioned on the NHS; it is contraindicated in uncontrolled hypertension, seizure disorders, and eating disorders.
- HRT manages perimenopausal symptoms and is broadly weight neutral — it is not a weight loss treatment and should not be used as one.
- All weight loss medications should be used alongside dietary changes, resistance training, and behavioural support, in line with NICE and NHS guidance.
Table of Contents
- Why Weight Gain Happens During Perimenopause
- Medications Used to Support Weight Loss in Perimenopause
- How These Treatments Are Prescribed on the NHS
- Safety Considerations and MHRA Guidance for Perimenopausal Women
- Lifestyle Approaches Recommended Alongside Medication
- When to Speak to Your GP About Perimenopausal Weight Concerns
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Why Weight Gain Happens During Perimenopause
Perimenopause — the transitional phase leading up to the final menstrual period — typically begins in a woman's mid-to-late 40s, though it can start earlier. During this time, oestrogen and progesterone levels fluctuate significantly before eventually declining. These hormonal shifts influence body composition and fat distribution, though it is important to recognise that overall weight gain during midlife is driven by a combination of hormonal, age-related, and lifestyle factors rather than hormonal changes alone.
One of the most consistently reported changes is an increase in abdominal (visceral) fat, even in women whose overall weight remains relatively stable. Falling oestrogen levels alter where the body preferentially stores fat, shifting it away from the hips and thighs towards the midsection. Visceral fat is metabolically active and is associated with an increased risk of cardiovascular disease and type 2 diabetes. In Europid women, a waist circumference of 80 cm or above indicates increased cardiometabolic risk; thresholds differ for women from South Asian, Chinese, Japanese, and other ethnic backgrounds, and your GP can advise on the appropriate reference range for you.
Additionally, perimenopausal women often experience:
-
Loss of lean muscle mass (sarcopenia) with advancing age, which reduces resting energy expenditure
-
Disrupted sleep due to night sweats and vasomotor symptoms, which can affect appetite-regulating hormones such as ghrelin and leptin
-
Mood changes and fatigue, which may reduce motivation for physical activity
Recognising these overlapping factors helps both patients and clinicians approach weight concerns with greater nuance. NICE guideline NG23 (Menopause: diagnosis and management) and resources from the British Menopause Society provide further context on the physiological changes of perimenopause.
Medications Used to Support Weight Loss in Perimenopause
Several licensed medications may be considered to support weight management in perimenopausal women. It is important to note that no weight loss medication is specifically licensed for perimenopause as an indication. These treatments are prescribed based on standard weight-management criteria, with perimenopausal status considered as part of the broader clinical picture. None of these medicines are recommended during pregnancy or breastfeeding; women of childbearing potential should use effective contraception and discuss pre-conception discontinuation timings with their clinician.
GLP-1 receptor agonists — such as semaglutide (Wegovy) and liraglutide (Saxenda) — are among the most clinically significant options currently available in the UK. These medicines mimic the action of glucagon-like peptide-1, a gut hormone that regulates appetite and insulin secretion. They slow gastric emptying, promote satiety, and reduce overall caloric intake. Both are subject to specific NICE eligibility criteria and stopping rules (see the prescribing section below).
Orlistat (available as Xenical on prescription or Alli over the counter) works differently, inhibiting pancreatic lipase to reduce dietary fat absorption by approximately 30%. It is generally considered less effective than GLP-1 receptor agonists but remains an option within some clinical pathways. Per the UK Summary of Product Characteristics (SmPC), treatment should be discontinued if weight loss is less than 5% after 12 weeks at the maintenance dose.
Naltrexone/bupropion (Mysimba) is a further licensed option in the UK, combining an opioid antagonist with a noradrenaline–dopamine reuptake inhibitor to reduce appetite and food cravings. It is not routinely commissioned on the NHS in most areas but may be available through specialist weight management services or private prescribing. It is contraindicated in uncontrolled hypertension, seizure disorders, and in those with a history of bipolar disorder or eating disorders; it also carries a precautionary note regarding mood and suicidal ideation, which is particularly relevant for perimenopausal women already at risk of mood disturbance.
Hormone replacement therapy (HRT) is not a weight loss treatment and should not be considered as such. HRT is indicated for the management of perimenopausal and menopausal symptoms, as supported by NICE NG23. Evidence suggests HRT is broadly weight neutral, though it may modestly influence fat distribution in some women. Any decision about HRT should be based on symptom control and an individual risk-benefit discussion with a GP or menopause specialist, not on expectations of weight loss.
How These Treatments Are Prescribed on the NHS
Access to weight loss medications on the NHS is governed by specific eligibility criteria set out in NICE technology appraisals and clinical guidelines (including NICE NG246, Obesity: identification and management, which replaces the earlier CG189). A broader assessment of health risk is required; perimenopausal weight gain alone is not sufficient grounds for prescribing.
Semaglutide (Wegovy) is recommended under NICE technology appraisal TA875 (2023) for adults with a BMI of 35 kg/m² or above alongside at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidaemia), or a BMI of 30–34.9 kg/m² in certain higher-risk groups. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, these thresholds are reduced by 2.5 kg/m². NICE specifies that Wegovy must be prescribed as part of a specialist weight management service. Treatment duration under TA875 is a maximum of two years; it should be stopped if less than 5% of initial body weight is lost after 6 months at the maintenance dose. Current NHS England commissioning and supply constraints mean access may be phased; your GP can advise on local availability.
Liraglutide (Saxenda) is recommended under NICE technology appraisal TA664 and, like semaglutide, must be initiated within a specialist weight management service — it is not recommended for routine initiation in primary care. Similar ethnicity-adjusted BMI thresholds and stopping rules apply (discontinue if less than 5% weight loss after 12 weeks at maintenance dose).
Orlistat indications are based on the licensed criteria set out in the BNF and SmPC: a BMI of 28 kg/m² or above with associated risk factors, or 30 kg/m² or above without. Orlistat may be initiated in primary care, subject to local formulary guidance. The same ethnicity-adjusted thresholds apply where relevant. It should be stopped if weight loss is less than 5% after 12 weeks.
Naltrexone/bupropion (Mysimba) is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with weight-related comorbidities, but is not routinely commissioned on the NHS; availability varies by area.
For perimenopausal women, a GP consultation should encompass:
-
BMI and waist circumference measurement, with ethnicity-appropriate thresholds
-
Assessment of cardiovascular and metabolic risk
-
Review of perimenopausal symptoms and suitability for HRT
-
Referral to a specialist weight management service if criteria are met
Private prescribing pathways exist for some of these medications, but patients should ensure they are assessed by a registered clinician, in line with MHRA guidance on safe online prescribing. Be aware that counterfeit GLP-1 receptor agonist pens have been identified in the UK; only obtain medicines through a registered pharmacy.
Safety Considerations and MHRA Guidance for Perimenopausal Women
Patient safety is paramount when considering any pharmacological intervention for weight management. Perimenopausal women have specific physiological considerations that warrant careful evaluation before starting treatment.
GLP-1 receptor agonists (semaglutide, liraglutide)
Common side effects include nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation. More serious risks include:
-
Pancreatitis: seek urgent medical attention for persistent, severe upper abdominal pain, which may radiate to the back
-
Gallbladder disease: GLP-1 receptor agonists are associated with an increased risk of gallstones and cholecystitis; report persistent upper abdominal pain to your clinician
-
Thyroid: animal studies have identified thyroid C-cell changes; a causal link in humans has not been established. UK SmPCs classify this as a precaution rather than a contraindication; discuss any personal or family history of thyroid conditions with your prescriber
-
Hypoglycaemia: risk is increased when used alongside insulin or sulfonylureas; dose adjustment of those medicines may be required
-
Insulin dose reduction: the MHRA has issued a Drug Safety Update warning that rapidly reducing insulin when starting a GLP-1 receptor agonist can precipitate diabetic ketoacidosis (DKA); any insulin adjustments must be made under medical supervision
-
Mood and mental health: the EMA/PRAC has reviewed GLP-1 receptor agonists for a potential signal of suicidal ideation; no causal link has been established to date, but perimenopausal women already at risk of anxiety or depression should be monitored closely
-
Drug interactions: GLP-1 receptor agonists slow gastric emptying, which may theoretically affect absorption of some oral medicines. Clinically significant interactions are uncommon; however, INR should be monitored more frequently in women taking warfarin. Note that transdermal HRT preparations are not affected by changes in gastric emptying
These medicines must not be used during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception throughout treatment and for a period after stopping, as specified in the relevant SmPC.
Orlistat
Orlistat reduces absorption of fat-soluble vitamins (A, D, E, and K). Vitamin D deficiency is already prevalent in perimenopausal women, and a daily multivitamin supplement taken at bedtime (separated from orlistat doses) is routinely recommended. Key interactions include: avoid use with ciclosporin (reduced ciclosporin levels); monitor INR closely in women taking warfarin. Rare cases of oxalate nephropathy have been reported with long-term use.
Bone health
Oestrogen decline during perimenopause increases osteoporosis risk. Rapid or substantial weight loss can exacerbate bone density loss; bone health monitoring is advisable, particularly with prolonged treatment.
Reporting side effects
Patients and healthcare professionals are encouraged to report suspected adverse effects from any medicine via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This helps the MHRA monitor the ongoing safety of medicines used in the UK.
Always consult a healthcare professional before starting any weight loss medication.
Lifestyle Approaches Recommended Alongside Medication
NICE and NHS guidance consistently emphasises that weight loss medications should be used as an adjunct to — not a replacement for — sustained lifestyle modification. This principle is especially relevant during perimenopause, where hormonal changes can undermine even well-established healthy habits, making a structured, evidence-based approach all the more important.
Dietary adjustments recommended for perimenopausal women include:
-
Prioritising protein-rich foods (lean meat, fish, legumes, dairy) to help preserve muscle mass
-
Reducing ultra-processed foods, refined carbohydrates, and added sugars, which can exacerbate insulin resistance
-
Ensuring adequate calcium and vitamin D intake to support bone health
-
Considering a Mediterranean-style dietary pattern, which has evidence supporting cardiovascular and metabolic benefits
The British Dietetic Association and NHS provide patient-facing resources on healthy eating during menopause, including guidance on calcium and vitamin D requirements.
Physical activity is equally important. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults. For perimenopausal women, resistance training (two or more sessions per week) is particularly beneficial for maintaining lean muscle mass and supporting metabolic rate. Weight-bearing exercise also contributes to bone density preservation.
Sleep and stress management should not be overlooked. Poor sleep — common during perimenopause due to vasomotor symptoms — disrupts cortisol and appetite-regulating hormones, making weight management significantly harder. NICE has recommended digital cognitive behavioural therapy for insomnia (CBT-I) as an effective intervention; Sleepio is one example of a digital CBT-I programme that has received a positive NICE recommendation and is available through some NHS services. Speak to your GP about what is available locally.
Behavioural support, such as that offered through NHS tier 2 weight management programmes or referral to a registered dietitian, can provide structured guidance and accountability. Medication is most effective when embedded within this broader framework of lifestyle change.
When to Speak to Your GP About Perimenopausal Weight Concerns
Many women normalise weight gain during perimenopause, assuming it is an inevitable and unmanageable consequence of ageing. Whilst hormonal and age-related changes do contribute, unexplained or rapid weight gain should always be assessed by a healthcare professional to rule out other underlying causes, such as hypothyroidism, polycystic ovary syndrome (PCOS), or insulin resistance.
Consider booking an appointment with your GP if you notice:
-
Unexplained weight gain over a short period without clear dietary or lifestyle changes
-
Significant increase in abdominal girth, which may indicate rising visceral fat and associated metabolic risk
-
Fatigue, low mood, or cognitive changes alongside weight changes, which may suggest thyroid dysfunction or other conditions
-
Difficulty losing weight despite consistent dietary and exercise efforts over several months
-
Symptoms of perimenopause (irregular periods, hot flushes, sleep disturbance) that are significantly affecting quality of life
Seek prompt medical review if you experience rapid, unexplained weight change accompanied by breathlessness or swelling (which may suggest a cardiac or renal cause), features suggestive of Cushing's syndrome (such as easy bruising, stretch marks, or central weight gain with thin limbs), or new excessive thirst and urinary frequency.
Your GP can arrange relevant blood tests — including thyroid function, fasting glucose, and lipid profile — to build a comprehensive picture of your metabolic health. In line with NICE NG23, routine measurement of sex hormone levels (such as FSH or oestradiol) is not recommended for diagnosing perimenopause in women aged 45 or over, as results can be misleading due to hormonal fluctuation; hormone testing is generally reserved for women under 45 or where premature ovarian insufficiency is suspected.
Your GP can also discuss whether you meet the criteria for referral to a specialist (tier 2 or tier 3) weight management service or a menopause clinic. Referral thresholds vary by local pathway but are broadly aligned with NICE NG246 criteria; your GP can advise on provision in your area. Early intervention is always preferable — addressing weight concerns during perimenopause can have lasting benefits for cardiovascular health, bone density, and overall wellbeing in the years ahead.
Frequently Asked Questions
Can I get weight loss pills for perimenopause on the NHS?
You can access weight loss medication on the NHS, but eligibility is based on your BMI and health risk profile rather than perimenopausal status alone. Semaglutide (Wegovy) and liraglutide (Saxenda) require referral to a specialist weight management service, while orlistat can be initiated in primary care if you meet the licensed BMI criteria. Your GP can assess whether you qualify and advise on local availability.
Will taking HRT help me lose weight during perimenopause?
HRT is not a weight loss treatment and should not be started with that expectation — evidence indicates it is broadly weight neutral, though it may modestly influence fat distribution in some women. HRT is indicated for managing perimenopausal symptoms such as hot flushes, night sweats, and sleep disturbance, and any decision to start it should be based on a risk-benefit discussion with your GP or a menopause specialist. If weight management is your primary concern, separate treatment options should be explored.
Are weight loss injections like semaglutide safe to use during perimenopause?
Semaglutide (Wegovy) can be prescribed to perimenopausal women who meet NICE eligibility criteria, but specific safety considerations apply, including monitoring for mood changes, gallbladder disease, and bone density loss associated with rapid weight reduction. The EMA has reviewed GLP-1 receptor agonists for a potential signal of suicidal ideation — no causal link has been confirmed, but women already experiencing perimenopausal mood disturbance should be monitored closely. Always discuss your full medical history, including any HRT use, with your prescribing clinician.
What is the difference between orlistat and GLP-1 receptor agonists for weight loss?
Orlistat works by blocking pancreatic lipase to reduce dietary fat absorption by around 30%, whereas GLP-1 receptor agonists such as semaglutide and liraglutide act on appetite-regulating pathways in the brain and gut to reduce hunger and slow gastric emptying. GLP-1 receptor agonists are generally considered more effective and require specialist initiation, while orlistat can be started in primary care and is also available over the counter at a lower dose. The right choice depends on your BMI, comorbidities, and individual clinical circumstances.
Can I take weight loss pills at the same time as HRT patches or tablets?
Transdermal HRT preparations (patches and gels) are not affected by GLP-1 receptor agonists, which slow gastric emptying and can theoretically alter absorption of some oral medicines. Oral HRT tablets are generally considered low-risk for clinically significant interactions with weight loss medications, but you should always inform your prescriber of all medicines you are taking so they can review your full regimen. If you take warfarin alongside any weight loss medication, more frequent INR monitoring is recommended.
What should I do if I'm gaining weight during perimenopause but don't qualify for prescription weight loss pills?
If you do not meet the BMI or comorbidity thresholds for prescription weight loss medication, your GP can still refer you to an NHS tier 2 weight management programme, which provides structured dietary, physical activity, and behavioural support. Resistance training at least twice a week, a protein-rich diet, and addressing sleep disruption caused by vasomotor symptoms are all evidence-based strategies that can meaningfully support weight management during perimenopause. It is also worth asking your GP to check thyroid function and fasting glucose, as underlying conditions can contribute to weight gain and are treatable.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
